Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-3000 in recent-onset atrial fibrillation
NCT04680026Phase 2Active, not recruiting
- Sponsor
- HUYABIO International, LLC
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of sulcardine in Atrial fibrillation (AFib) (5 arms), sponsored by HUYABIO International, LLC. Primary endpoints: Adverse Events at 30 days, Heart Rate and 3 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
sulcardine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04680026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680026.